Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
1.56 -0.13 (-7.69%) 11:46 ET [NASDAQ]
1.55 x 61 1.56 x 400
Realtime by (Cboe BZX)
1.55 x 61 1.56 x 400
Realtime 1.5900 -0.1000 (-5.92%) 09:23 ET
Quote Overview for Thu, Apr 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.54
Day High
1.63
Open 1.54
Previous Close 1.69 1.69
Volume 603,769 603,769
Avg Vol 2,226,812 2,226,812
Stochastic %K 37.44% 37.44%
Weighted Alpha -37.61 -37.61
5-Day Change -0.5500 (-26.19%) -0.5500 (-26.19%)
52-Week Range 0.7650 - 4.0800 0.7650 - 4.0800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 233,698
  • Shares Outstanding, K 138,283
  • Annual Sales, $ 850 K
  • Annual Income, $ -49,380 K
  • EBIT $ -55 M
  • EBITDA $ -55 M
  • 60-Month Beta 1.40
  • Price/Sales 364.42
  • Price/Cash Flow N/A
  • Price/Book 2.46

Options Overview Details

View History
  • Implied Volatility 133.37% ( +7.22%)
  • Historical Volatility 114.84%
  • IV Percentile 6%
  • IV Rank 1.38%
  • IV High 649.12% on 03/21/25
  • IV Low 126.15% on 04/02/25
  • Put/Call Vol Ratio 2.88
  • Today's Volume 221
  • Volume Avg (30-Day) 4,736
  • Put/Call OI Ratio 1.05
  • Today's Open Interest 59,187
  • Open Int (30-Day) 34,093

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 7
  • High Estimate -0.10
  • Low Estimate -0.15
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3300 +16.54%
on 04/01/25
Period Open: 2.7300
2.9800 -47.99%
on 03/05/25
-1.1800 (-43.22%)
since 03/03/25
3-Month
1.3300 +16.54%
on 04/01/25
Period Open: 1.5600
4.0800 -62.01%
on 02/11/25
-0.0100 (-0.64%)
since 01/03/25
52-Week
0.7650 +102.61%
on 07/05/24
Period Open: 1.8500
4.0800 -62.01%
on 02/11/25
-0.3000 (-16.22%)
since 04/03/24

Most Recent Stories

More News
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

CMPX : 1.5500 (-8.28%)
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

CMPX : 1.5500 (-8.28%)
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

CMPX : 1.5500 (-8.28%)
Top 3 High-Momentum Companies Analysts Are Still Bullish On

Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.

AVAV : 118.59 (-6.50%)
AMPX : 2.53 (-8.33%)
CMPX : 1.5500 (-8.28%)
ALLT : 5.32 (-7.48%)
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

CMPX : 1.5500 (-8.28%)
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted expert predictions...

ONCY : 0.5005 (-4.23%)
TYRA : 8.15 (-5.78%)
ZNTL : 1.2850 (-5.17%)
ONC.TO : 0.71 (-6.58%)
CMPX : 1.5500 (-8.28%)
CCCC : 1.4150 (-6.91%)
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

CMPX : 1.5500 (-8.28%)
Compass Therapeutics Appoints Barry Shin as Chief Financial Officer

Compass Therapeutics announces Barry Shin as CFO, enhancing financial strategy amid key clinical developments in 2025.Quiver AI SummaryCompass Therapeutics, Inc. has appointed Barry Shin as Chief Financial...

CMPX : 1.5500 (-8.28%)
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

CMPX : 1.5500 (-8.28%)
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

CMPX : 1.5500 (-8.28%)

Business Summary

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 2.9500
2nd Resistance Point 2.6900
1st Resistance Point 2.1900
Last Price 1.5500
1st Support Level 1.4300
2nd Support Level 1.1700
3rd Support Level 0.6700

See More

52-Week High 4.0800
Fibonacci 61.8% 2.8137
Fibonacci 50% 2.4225
Fibonacci 38.2% 2.0313
Last Price 1.5500
52-Week Low 0.7650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades